What 4 Analyst Ratings Have To Say About Legend Biotech

Throughout the last three months, 4 analysts have evaluated Legend Biotech LEGN, offering a diverse set of opinions from bullish to bearish.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $82.75, a high estimate of $94.00, and a low estimate of $65.00. This current average has decreased by 11.02% from the previous average price target of $93.00.

Deciphering Analyst Ratings: An In-Depth Analysis

The perception of Legend Biotech by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Legend Biotech. This information provides a snapshot of how analysts perceive the current state of the company.
• Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Legend Biotech compared to the broader market.
• Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Legend Biotech's stock. This examination reveals shifts in analysts' expectations over time.

Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Legend Biotech's market standing. Stay informed and make data-driven decisions with our Ratings Table.

Stay up to date on Legend Biotech analyst ratings.

Unveiling the Story Behind Legend Biotech

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy is for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America.

Legend Biotech's Financial Performance

Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.

Revenue Growth: Legend Biotech's remarkable performance in 3 months is evident. As of 30 September, 2023, the company achieved an impressive revenue growth rate of 250.91%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.

Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -64.79%, the company may need to address challenges in effective cost control.

Return on Equity (ROE): Legend Biotech's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -4.53%, the company may face hurdles in achieving optimal financial returns.

Return on Assets (ROA): Legend Biotech's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -3.3%, the company may face hurdles in achieving optimal financial performance.

Debt Management: Legend Biotech's debt-to-equity ratio is below the industry average at 0.24, reflecting a lower dependency on debt financing and a more conservative financial approach.

The Basics of Analyst Ratings

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.

This article was generated by Benzinga's automated content engine and reviewed by an editor.